Cytek Biosciences (NASDAQ:CTKB - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data after the market closes on Thursday, May 8th. Analysts expect Cytek Biosciences to post earnings of ($0.04) per share and revenue of $43.18 million for the quarter.
Cytek Biosciences Stock Performance
Shares of CTKB traded up $0.16 during mid-day trading on Friday, hitting $3.86. 497,366 shares of the stock were exchanged, compared to its average volume of 713,440. The company has a market cap of $494.45 million, a PE ratio of -48.24 and a beta of 1.41. Cytek Biosciences has a 52-week low of $3.27 and a 52-week high of $7.63. The firm has a 50-day moving average of $4.00 and a two-hundred day moving average of $5.31.
Wall Street Analysts Forecast Growth
Several equities analysts have commented on the stock. Piper Sandler lowered their price objective on shares of Cytek Biosciences from $8.50 to $8.00 and set an "overweight" rating for the company in a research report on Tuesday, March 4th. Stephens reaffirmed an "overweight" rating and issued a $6.00 price target on shares of Cytek Biosciences in a report on Wednesday, March 19th. Finally, The Goldman Sachs Group set a $5.25 price objective on Cytek Biosciences in a research note on Sunday, February 2nd.
Get Our Latest Report on Cytek Biosciences
About Cytek Biosciences
(
Get Free Report)
Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.
Further Reading
Before you consider Cytek Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytek Biosciences wasn't on the list.
While Cytek Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
